# Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer

> **NCT06550453** · PHASE4 · RECRUITING · sponsor: **yangjianjun** · enrollment: 20 (estimated)

## Conditions studied

- Locally Advanced Colorectal Cancer

## Interventions

- **DRUG:** Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)

## Key facts

- **NCT ID:** NCT06550453
- **Lead sponsor:** yangjianjun
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2025-01-15
- **Final completion:** 2026-01-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06550453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06550453, "Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06550453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*